Core Insights - Merus N.V. has initiated a phase 2 trial for petosemtamab, a novel treatment for heavily pretreated metastatic colorectal cancer (mCRC) [1][2] - Petosemtamab is a Biclonics® antibody targeting EGFR and LGR5, designed to inhibit cancer cell signaling and enhance immune response [4][5] - The trial aims to evaluate the safety and antitumor activity of petosemtamab in patients who have undergone prior anti-EGFR therapy [2][3] Company Overview - Merus N.V. is a clinical-stage oncology company focused on developing innovative bispecific and trispecific antibody therapeutics, known as Multiclonics® [5] - The company utilizes industry-standard processes to manufacture its antibodies, which exhibit characteristics similar to conventional monoclonal antibodies, such as long half-life and low immunogenicity [5] Product Details - Petosemtamab (MCLA-158) is engineered to have three mechanisms of action: inhibiting EGFR signaling, promoting EGFR internalization and degradation, and enhancing antibody-dependent cellular cytotoxicity and phagocytosis [4] - Preclinical studies indicate that petosemtamab shows superior activity compared to cetuximab, a standard treatment for mCRC [3]

Core Insights - Petosemtamab (MCLA-158) demonstrates clinically meaningful efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in a Phase 2 trial, with a 40.4% overall response rate and a median overall survival of 12.5 months [1][3][4] Company Overview - Merus N.V. is a clinical-stage oncology company focused on developing innovative full-length multispecific antibodies, known as Biclonics® and Triclonics® [6] - The company is preparing for a conference call to discuss updated clinical data on petosemtamab, scheduled for December 7, 2024 [2][4] Clinical Data Summary - As of November 6, 2023, 54 patients were treated with 1500 mg of petosemtamab, with 47 evaluable for response, yielding a 40.4% overall response rate [3] - The median duration of response was 7.2 months, median progression-free survival was 5.1 months, and median overall survival was 12.5 months [3] - A new dose-comparison cohort was established with 42 patients randomized to receive either 1500 mg or 1100 mg, showing promising results at both dose levels [3] Safety Profile - Petosemtamab was well tolerated across both dose levels, with no new safety signals reported and no grade 5 treatment-emergent adverse events [3][5] Industry Context - HNSCC is the sixth most common cancer globally, with over 930,000 new cases and 465,000 deaths reported in 2020, and the incidence is expected to rise by 30% by 2030 [4] - Current standard therapies for HNSCC have poor prognosis, highlighting the need for new treatment options like petosemtamab [4]

Core Viewpoint - Merus NV (NASDAQ:MRUS) has seen a positive market reaction following Goldman Sachs' initiation of coverage with a "buy" rating, driven by the potential growth from its cancer treatment [1]. Group 1: Stock Performance - MRUS stock is currently up 3.4% at $44.40, recovering from a recent decline and aiming to end an eight-day losing streak [1][2]. - The stock dropped below its long-term support at the 200-day moving average, which was at $42, coinciding with a pre-bull gap level from April [2]. - Year-to-date, MRUS has increased by 58.3% [2]. Group 2: Analyst Ratings - All 17 analysts covering Merus stock have a "buy" or better rating, indicating strong bullish sentiment [2]. - The 12-month consensus price target for MRUS is $86.60, representing a 98.4% premium to current levels [2]. Group 3: Options Market Sentiment - Options traders are optimistic, with a 50-day call/put volume ratio of 6.88, ranking in the 93rd percentile of its annual range [3].

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: Guggenheim Securities Healthcare Innovation Conference (fireside chat): Tuesday, November 12 at 9:30 a.m. ETStifel 2024 Healthcare Confer ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for zenocutuzumab (Zeno) Biologics License Application (BLA) currently under priority review. The US FDA ha ...

Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this company would post a loss of $0.76 per share when it actually produced a loss of $0.81, delivering a surprise of -6.58%.Over the last four quarters, the company has surpassed con ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for rapid oral presentation at ESMO® Asia Congress 2024 Based on the Company’s current operating plan, existing cash, cash equivalents, and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) --  Merus N.V. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands Not Applicable (State or other jurisdiction of ...

H p F 1 198 1 ll t E I 4011 the " 1 1 in 8.8% 电影 en HD 1999 1 I I TI i r I 1982 i Income. 40 F H TICH STATE P 196 H 1 1 18 la lar 4-0 E 1 THE OWNER 1 - 1 8 luismmolina Merus N.V. (NASDAQ:MRUS) is a Dutch company that has seen its stock nearly triple since I covered it in April last year. At that time, I had some doubts about its lead molecule zenocutuzumab, a HER2 and HER3 targeting bispecific molecule targeting NRG1+ cancer as monotherapy. My doubts came from the small and early stage nature of the registr ...